Abstract
ObjectiveTo identify the disturbances in glucose and lipid metabolism observed in Type 2 Diabetes Mellitus (T2DM), we examined the interaction and contribution of multiple tissues (liver, heart, muscle, and brown adipose tissue) and monitored the effects of the PPARγ agonist rosiglitazone (RGZ) on metabolism in these tissues.Design and MethodsRates of [18F]FDG and [11C]Palmitate uptake and utilization in the Zucker Diabetic Fatty (ZDF) rat were quantified using non-invasive positron emission tomography (PET) imaging and quantitative modeling in comparison to lean Zucker rats. Furthermore, we studied two separate groups of RGZ-treated and untreated ZDF ratsResultsGlucose uptake is impaired in ZDF brown fat, muscle, and heart tissues compared to leans, while RGZ treatment increased glucose uptake compared to untreated ZDF rats. Fatty acid (FA) uptake decreased, but FA flux increased in brown fat and skeletal muscle of ZDF rats. RGZ treatment increased uptake of FA in brown fat, but decreased uptake and utilization in liver, muscle and heart.ConclusionOur data indicate tissue-specific mechanisms for glucose and FA disposal as well a differential action of insulin-sensitizing drugs to normalize substrate handling and highlight the role that pre-clinical imaging may play in screening drugs for obesity and diabetes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
